New Systematic Review Identifies Chronic Stress as a Biological Driver of Tumor Progression and Immune Suppression

Wroclaw Medical University study reveals how chronic stress acts as a biological driver in cancer, calling for integrated psychological care in standard oncology.

By: AXL Media

Published: Mar 24, 2026, 11:50 AM EDT

Source: Information for this report was sourced from Wroclaw Medical University

The Persistent Biological Strain of Oncological Distress

In the clinical setting of oncology, stress is a constant and multi-dimensional companion that often persists long after active therapy concludes. A systematic review conducted by Wroclaw Medical University defines chronic stress not as a temporary emotional reaction, but as a long-term strain on the body's adaptive capacity. When a patient remains in "danger mode" for weeks or months, the systems responsible for threat response stay active, leading to measurable physiological shifts. According to lead author Dr. Katarzyna Herbetko, this persistent state acts as a biological catalyst that can weaken the body’s natural defenses and influence the overall course of the disease.

The Triple Mechanism of Stress Induced Progression

The researchers identified three primary, interrelated stages through which chronic stress interacts with cancer biology. First, the "hormonal alarm" phase causes a persistent activation of the hypothalamic-pituitary-adrenal (HPA) axis, leading to elevated levels of cortisol and adrenaline. Second, these hormones suppress the immune system’s ability to conduct "immune surveillance," shifting the body toward a state of chronic, low-grade inflammation. Finally, at the tissue level, this inflammatory environment can facilitate angiogenesis—the creation of new blood vessels—and cancer cell migration, while simultaneously increasing the tumor’s resistance to standard treatments.

Varying Impact Across Different Cancer Diagnoses

A significant conclusion of the 2026 review is that the biological impact of stress is not uniform across all malignancies. In cancers with higher survival rates, such as breast and prostate cancer, stress typically manifests as chronic uncertainty and fear of recurrence, primarily involving adrenergic signaling. In contrast, cancers with poorer prognoses, such as pancreatic and ovarian cancer, often show more severe psychological distress and depression that can actually precede the formal diagnosis. In these cases, systemic stress is dominated by cytokine mechanisms and elevated IL-6 levels, suggesting that psychological symptoms may be deeply intertwined with the early biological onset of the disease.